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Abstract
Pancreatic b-cells are metabolic sensors involved in the control of glucose homeostasis. This particular cell type
controls insulin secretion through a fine-tuned process, which dregulation have important pathological conse-
quences, such as observed during type 2 diabetes. We recently implicated E2F1 in the control of glucose homeos-
tasis. First we showed that E2f1-/- mice have decreased pancreatic size, as the result of impaired postnatal
pancreatic growth. We observed in this study that E2F1 was highly expressed in non-proliferating pancreatic b-
cells, suggesting that E2F1, besides the control of b-cell number could have a role in pancreatic b-cell function. We
demonstrate in our recent study, both in vitro and in vivo that E2F1 directly regulates the expression of Kir6.2, a key
component of the KATP channel involved in the regulation of glucose-induced insulin secretion in pancreatic b-
cells. Expression of Kir6.2 is lost in pancreas of E2f1-/- mice, resulting in insulin secretion defects in these mice.
Furthermore, we demonstrated by in tissue chromatin immunoprecipitation analysis that regulation of Kir6.2 expres-
sion by E2F1 follows the same regulatory pathway that the classical E2F1 target genes, implicating the participation
of CDK4 and retinoblastoma protein. Moreover, in this context, E2F1 transcriptional activity is regulated by glucose
and insulin through the CDK4-dependent inactivation of the pRB protein. In summary we provide evidence that
the CDK4-pRB-E2F1 regulatory pathway is involved in glucose homeostasis. In our recent study we decipher a new
function for these factors in the control of insulin secretion and open up new avenues for the treatment of meta-
bolic diseases, in particular type 2 diabetes.
Introduction
The synthesis of insulin occurs in a specific compart-
ment of the islet of Langerhans, the pancreatic b-cells.
In normal conditions, transient hyperglycemia requires
increased insulin secretion, which could be obtained
through several adaptations of the b-cell, i.e. hyperplasia
(increase in number) or hypertrophy (increase in size)
[1,2]. This transient increase in b-cell proliferation to
properly secrete sufficient amount of insulin is required
to restore normal glucose level, yet defect in this process
could have pathological consequences. Diabetes mellitus
are multifactorial disorders characterized by an autoim-
mune b-cell destruction (type 1) or a combination of
insulin resistance in peripheral tissues and b-cell failure
(type 2). The resulting hyperglycemia is responsible for
several long-term complications, such as retinopathy,
neuropathy, kidney diseases or cardiovascular diseases.
During type 2 diabetes, the chronic hyperglycemic state
will enforce insulin secretion, and thus b-cell function,
finally leading to a decrease in b-cell mass. Therefore,
understanding how b-cells proliferate and function is of
utmost importance and could have strong implications
in the development of new therapeutic strategies for
type 1 and 2 diabetes. Participation of cell cycle regula-
tors in this process can be predicted, and has been
demonstrated, as described below. However, the aim of
this paper is to comment our recent data demonstrating
that, in addition to their role in the control of cell mass,
cell cycle regulators directly regulate b-cell functions [3].
Discussion
Cell cycle, b-cell and more
E2F transcription factors are often depicted as the ulti-
mate effectors of the G1/S transition of the cell cycle.
When bound to DNA, they exist either as free E2F/DP
heterodimers, or associated in larger complexes contain-
ing members of the retinoblastoma family (pRB, p107,
p130) and members of the cyclin/cdk protein families.
Cyclin-dependent kinases (CDK) define a family of ser-
ine/threonine protein kinases that phosphorylate a num-
ber of substrates mainly implicated in cell cycle
progression and transcription. Association of E2Fs with
proteins of the pRB family facilitates active repression
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lysine/arginine methyl-transferases [5]. Subsequent
phosphorylation of the retinoblastoma protein by the
cyclin/CDK complexes results in the release of the E2F
transcription factors and activation of the transcription
of genes required for progression through G1 into the S
phase of the cell cycle. CDKs ultimately translate exter-
nal signaling into transcriptional response, which is the
final step of the regulatory cascade [6]. This makes the
CDK-pRB-E2Fs potential candidates for the control of
the crosstalk between proliferative stimuli and metabolic
response. E2Fs functions are not restricted to the con-
trol of cell proliferation and it is now accepted that
E2Fs participate in cellular processes beyond the cell
cycle [7]. This has been extensively demonstrated
through the characterization of E2fs-null mouse models
[8] and the number of genes identified as E2F targets
encoding factors involved in DNA replication, mitosis,
DNA repair, apoptosis, differentiation, and development
(reviewed in [9]). Of particular interest is the observa-
tion that E2Fs, pRB, and cdk4 could be involved in the
regulation of a metabolic network, including the control
of adipose tissue function [10,11].
Proliferation of b-cells is a key mechanism to maintain
postnatal b-cell mass [12,13], and is the primary
mechanism for b-cell regeneration [14-16]. It is now
clear that pancreatic b-cells are able to replicate, albeit
the origin of newly formed islets remains controversial.
However, the mechanisms controlling b-cell replication
unequivocally require cell cycle regulation. Gene inacti-
vation studies of cell cycle regulators underscore the
important role for these proteins in maintaining the b-
cell population. Together with our previous observation
that E2f1 -/- mice have decreased b-cell mass, due to
decreased proliferation [17], other cell cycle regulators
have been implicated in this process (for review, see
[18]. Similar to E2f1-/-, Cyclin D1+/-; Cyclin D2-/- [19],
Cyclin D2 -/- [15], and Cdk4 -/- [20] mice have
decreased b-cell mass. Conversely, mice with gene inac-
tivation of the cell cycle inhibitors p27 [21,22], p16
INK4A
[23] have increased islet mass. Interestingly, genetic res-
cue of a mutant Cdk4 insensitive to INK4 inhibition
(CDK4
R24C)i naCdk4-null background results in nor-
mal b-cell mass, suggesting a key role for CDK4 in con-
trolling proliferation of b-cell [24].
E2F1 in the control of b-cell function and insulin secretion
We previously evaluated the effects of E2F1 on glucose
homeostasis. E2f1 -/- mice show an overall reduction in
pancreatic size, as the result of impaired postnatal pan-
creatic growth [17]. E2F1 is not involved in embryonic
b-cell development, since E2F1 is expressed at the final
step of pancreas development, as demonstrated by in
situ hybridizations. Because of the disproportionate
small pancreas E2f1 -/- b-cells secrete insufficient
amounts of insulin in response to a glucose load, result-
ing in glucose intolerance. However, despite this
decreased insulin secretion, these animals were pro-
tected for the development of diabetes because of a dra-
matic increase in insulin sensitivity in other tissues,
mainly adipose tissue [25]. In contrast, E2f1/E2f2 double
KO mice are diabetic, showing exocrine pancreatic
insufficiency, indicating that E2fs gene dosage and/or
tissue specificity are critical for glucose homeostasis and
pancreatic function [26,27]. These observations suggest
however that E2F1 and E2F2 might cooperate to regu-
late b-cell mass and functions through cell-autonomous
[3,17] and non-cell autonomous [26,28] effects. Surpris-
ingly, we observed that E2F1 was highly expressed in
non-proliferating adult pancreatic b-cells [17], suggest-
ing that besides its impact on b-cell number, E2F1
could also play a role in pancreatic b-cell function and
insulin secretion.
Pancreatic b-cell KATP channels are composed by the
heteromeric association of the sulfonylurea receptor 1
(SUR1) with the K
+ ATP channel inward rectifier
(KIR6.2). These channels play a critical role in the regu-
lation of glucose-induced insulin secretion by control-
ling membrane polarization [29,30]. The observation
that Kir6.2 -/- mice display defective insulin secretion
and increased insulin sensitivity is interesting [31], since
it strongly resembles a particular phenotype of E2f1-/-
mice [17]. Global gene expression analysis of E2f1+/+
and -/- pancreas revealed that the mRNA and protein
levels of Kir6.2 were decreased. Most importantly, we
demonstrated that Kir6.2 is a bona fide E2F1 target
gene, as observed by chromatin immunoprecipitation
performed on pancreas and isolated islet tissues. Most
importantly, rescue of Kir6.2 expression in E2f1 -/- iso-
lated islets restored glucose-stimulated insulin secretion,
confirming that E2F1 exerts cell-autonomous effects on
insulin secretion through its transcriptional control of
Kir6.2 expression [3]. Furthermore, since Kir6.2 tran-
scription is positively regulated by glucose, we studied
the impact of glucose and glucose-stimulated insulin in
the control of CDK4 activity and subsequent E2F1-
dependent transcription. Our data demonstrated that
glucose-stimulated insulin secretion triggers CDK4-
dependent pRb phosphorylation in the b-cell, and subse-
quent transcriptional activation of the Kir6.2 gene by
E2F1/DP-1 heterodimers. Finally, chemical invalidation
of CDK4 activity, through the use of a specific inhibitor,
resulted in glucose intolerance and impaired glucose-sti-
mulated insulin secretion in mice, confirming a role for
the CDK4-pRB-E2F1 pathway in insulin secretion pro-
cess. Altogether, our data provide evidence that the
CDK4-pRB-E2F1 pathway directly contributes to insulin
secretion through the regulation of Kir6.2 expression in
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reveal a novel feed-back control mechanism of the insu-
lin response.
Conclusion
We demonstrated that E2F1 transcriptional activity is
controlled in pancreatic b-cells by insulin signaling sec-
ondary to glucose-induced insulin secretion [3]. How
E2F1 can mediate both a proliferative (during post-natal
growth or regeneration) or/and a metabolic response
(during adulthood) in pancreatic b-cells in a coordinated
manner is still not clear. Interestingly, insulin is an
important b-cell proliferating factor, as evidenced by
studies using b-cell specific inactivation of the insulin
receptor (IR) in mice which resulted in a decrease in b-
cell mass [32-34] or treatment of b-cell lines with IR
siRNA which reduced proliferation rates of Min6 cells
[35]. On the other hand, insulin has been shown to
exert through an autocrine effect a feedback regulation
on metabolic gene transcription, such as insulin itself
(for review, [36]). Insulin signaling activation ultimately
results in a specific metabolic response in b-cells. Since
our recent findings indicate that the CDK4-pRB-E2F1
pathway is regulated by insulin, we can hypothesize that
both the proliferative and metabolic effects of insulin on
b-cells are mediated by the increase of CDK4 activity
and subsequent E2F1 transcriptional activity. This would
further suggest that both cell proliferation and metabolic
responses are intimately linked, and regulated by the
same upstream factors. In agreement with this hypoth-
esis, caAKT
Tg transgenic mice deficient in Cdk4 display
reduced b-cell proliferation, demonstrating that AKT
induces b-cell proliferation in a CDK4-dependent man-
ner [37]. Which is the pathway leading to cdk4-RB-E2F1
activation is largely unknown. One of the central ele-
ments that transduce signals from nutrient availability is
the mTOR pathway.(Wullschleger et al., 2006). Strik-
ingly, the metabolic phenotype of E2F1-/- mice is also
reminiscent to the phenotype of mice carrying inactivat-
ing mutations in the mTOR substrate S6K1 (Pende et
al., 2000; Ohanna et al., 2005; Aguilar et al., 2007; Um
et al., 2004). Both E2F1-/- and S6K1-/- mice show
impaired metabolism in pancreatic b-cells, adipose tis-
sue, muscle, and likely in other tissues with metabolic
functions, such as liver or brown adipose tissue. This
strongly suggests a cross talk between the mTOR-S6K
and cdk4-RB-E2F1 pathways. We speculate that the
mTOR-S6K pathway controls metabolic processes, at
least in part through regulation of the cdk4-pRB-E2F1
activity. The whole transcriptional program controlled
by the CDK4-pRB-E2F1 pathway in endocrine pancreas
remains, however largely unknown, and the signals and
molecular mechanisms that underly the particular
contribution of E2F1, CDK4 and pRB in metabolic ver-
sus proliferative response remains to be resolved.
We believe that the identification of new interacting
pathways involved in the control of metabolism will
open-up new perspectives for genetic studies in human
population. The possible correlation between increased
expression, or the presence of polymorphisms in any of
the proteins studied in this work will help to identify a
subset of subjects with increased risk to develop obesity-
induced type II diabetes. Finally, we expect that this
work will contribute to define new therapeutic strategies
to combat type II diabetes.
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